|
|||||||
Bildnachweis: Fotolia | ![]() |
||||||
>
Zurück
|
|||||||
![]() |
|
Werbung
Quelle: Medlinie Abstract
HIV-Infektionen (AIDS): Seit Einführung der modernen antiretroviral
wirkenden Medikamente hat sich das im Vergleich zur Gesamtbevölkerung
in der Vergangenheit dramatisch erhöhte zusätzliche Sterberisiko
bei HIV-Patienten deutlich vermindert.
Die vollständige englischsprachige Kurzversion dieser Studie (sog. MEDLINE Abstract) finden Sie hier
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA.
2008 Jul 2;300(1):51-9. PMID: 18594040 OBJECTIVE: To evaluate changes in the mortality gap between HIV-infected individuals and the general uninfected population. DESIGN, SETTING, AND POPULATION: Mortality following HIV seroconversion in a large multinational collaboration of HIV seroconverter cohorts (CASCADE) was compared with expected mortality, calculated by applying general population death rates matched on demographic factors. A Poisson-based model adjusted for duration of infection was constructed to assess changes over calendar time in the excess mortality among HIV-infected individuals. Data pooled in September 2007 were analyzed in March 2008, covering years at risk 1981-2006. MAIN OUTCOME MEASURE: Excess mortality among HIV-infected individuals compared with that of the general uninfected population. RESULTS: Of 16,534 individuals with median duration of follow-up of 6.3 years (range, 1 day to 23.8 years), 2571 died, compared with 235 deaths expected in an equivalent general population cohort. The excess mortality rate (per 1000 person-years) decreased from 40.8 (95% confidence interval [CI], 38.5-43.0; 1275.9 excess deaths in 31,302 person-years) before the introduction of highly active antiretroviral therapy (pre-1996) to 6.1 (95% CI, 4.8-7.4; 89.6 excess deaths in 14,703 person-years) in 2004-2006 (adjusted excess hazard ratio, 0.05 [95% CI, 0.03-0.09] for 2004-2006 vs pre-1996). By 2004-2006, no excess mortality was observed in the first 5 years following HIV seroconversion among those infected sexually, though a cumulative excess probability of death remained over the longer term (4.8% [95% CI, 2.5%-8.6%] in the first 10 years among those aged 15-24 years).
|
[an error occurred while processing this directive]
|
Bio-Nutzhanf-Produkte: umweltbewußte Anwender reiner Naturprodukte wollen die Kräfte der Natur und die
unverfälschten Inhaltsstoffe ausgewählter Kulturpflanzen nutzen.
Das innovative österreichische Unternehmen Deep Nature Project stellt in enger Zusammenarbeit mit ausgewählten
Bio-Landwirten qualitativ hochwertige Nutzhanf-Produkte
der Marke
MEDIHEMP her,
die ausschließlich aus legalem, EU-zertifiziertem Saatgut
gezogen werden und die Cannabinoide
Cannabidiol (CBD) und Cannabigerol (CBG) enthalten.
Innovative Kaltpressverfahren
erlauben es, aus dem extrem balaststoffreichen Nutzhanf
wertvolle Nahrungsmittel in Bio-Qualität herzustellen (Zitat: Wikipedia).
> zum online Shop
[an error occurred while processing this directive] |
|
Werbung: Copyright © LaHave Media Services Limited |